跳至主要内容
临床试验/NCT07266064
NCT07266064已完成不适用

Repeated Botulinum Toxin Type A Injections on the Masseter Muscle of Individuals With Sleep Bruxism: A Longitudinal Ultrasonographic Study.

Melek Volkan Yazici2 个研究点 分布在 1 个国家目标入组 27 人开始时间: 2024年1月2日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
27
试验地点
2
主要终点
Ultrasonographic imaging

研究概览

简要总结

This study investigates whether repeated botulinum toxin type A (BoNT-A) injections used to manage sleep bruxism lead to structural changes-specifically intramuscular fat accumulation-in the masseter muscle. Adults with probable sleep bruxism receive BoNT-A injections every six months and undergo ultrasound evaluations before each injection. By tracking fat percentage in the masseter muscle over multiple treatment cycles, the study aims to determine whether long-term BoNT-A use causes progressive structural alterations or remains safe for repeated clinical use.

详细描述

Botulinum toxin type A (BoNT-A) is commonly used for the management of sleep bruxism, yet concerns persist regarding its long-term effects on muscle structure, including the possibility of intramuscular fat accumulation in the masseter muscle. This prospective longitudinal study follows adults with probable sleep bruxism who receive bilateral BoNT-A injections at six-month intervals. Ultrasound imaging is performed immediately before each injection, resulting in four injection cycles and five standardized ultrasound assessments.

Intramuscular fat percentage is quantified from B-mode images at rest and during maximum voluntary contraction using binary segmentation techniques. By examining changes over repeated treatment cycles, the study evaluates whether BoNT-A leads to progressive fat infiltration or instead demonstrates a stable or adaptive pattern. Findings will help clarify the structural safety of long-term BoNT-A use in non-spastic masticatory muscles and guide clinical decision-making for ongoing bruxism management.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Screening
盲法
None

盲法说明

The radiologist who acquired the ultrasonographic data and the researcher who performed the cross-sectional fat infiltration analysis were completely blinded to each other's procedures.

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adults aged 18 years or older.
  • Clinical diagnosis of probable sleep bruxism according to the international consensus criteria proposed by Lobbezoo et al.
  • Indication for BoNT-A injection in the masseter muscle due to bruxism-related pain or muscle hypertrophy.
  • Willingness to undergo repeated BoNT-A injections at six-month intervals.
  • Willingness to participate in ultrasonographic evaluations at each follow-up visit.

排除标准

  • Presence of neurological or neuromuscular disorders affecting the masticatory muscles (e.g., dystonia, myasthenia gravis).
  • History of orofacial trauma, temporomandibular joint dysfunction, or maxillofacial surgery.
  • Systemic diseases that may affect neuromuscular transmission or muscle metabolism.
  • Use of medications known to interfere with neuromuscular function, including aminoglycoside antibiotics or corticosteroids.

结局指标

主要结局

Ultrasonographic imaging

时间窗: From enrollment to 6 months

Cross-sectional imaging was obtained from the same anatomical plane. The probe position was determined at each visit using consistent anatomical landmarks-specifically the lower border of the mandibular corpus and the thickest region of the masseter muscle. The imaging plane part of the masseter, located between the posterior border adjacent to the parotid gland and the anterior border of the mandibular ramus. Ultrasonographic images were acquired both at rest (RST) and during maximum voluntary contraction (MVC) under identical device settings by the same experienced radiologist.

次要结局

未报告次要终点

研究者

发起方
Melek Volkan Yazici
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Melek Volkan Yazici

Associate Professor

Yuksek Ihtisas University

研究点 (2)

Loading locations...

相似试验

招募中
3 期
Safety and efficacy of botulinum toxin A in patients with posttraumatic headache: a double-blind, randomized, placebo-controlled, parallel-group trial and investigation of neuro-inflammatory biomarkers as predictors of efficacy.
2024-515901-24-00Rigshospitalet80
尚未招募
不适用
Botulinum toxin type A injections in stiff knee gait.In the Netherlands live about 18.000 Cerebro Vascular Accident (CVA)-patients which discover problems with walking caused by insufficient footclearance. Causes of problems with the footclearance during the swing phase of gait are a combination of diminished dorsal flexion of the ankle, knee flexion and hip flexion. A diminished knee flexion during swing is defined a stiff knee gait. A stiff knee gait is often caused by an overactivity of the m. rectus femoris. Keywords: stroke, stiff knee gait
NL-OMON29171Roessingh Research and DevelopmentRoessinghsbleekweg 337577 AH Enschede26
已完成
不适用
The effect of repeated botulinum toxin A therapy combined intensive rehabilitation on lower limb spasticity in post- stroke patients.Chronic stroke patients
JPRN-UMIN000033463The Jikei University School of Medicine40
已完成
不适用
Subepithelial injection of botulinum toxin A for non-neurogecic overactive bladderon-neurogenic overactive bladder
JPRN-UMIN000001422ational Center for Geriatrics & Gerontology45
已完成
不适用
Subepithelial injection of botulinum toxin A for neurogecic detrusor overactivity (NDO) due to spinal cord injuryeurogenic detrusor overactivity
JPRN-UMIN000001421ational Center for Geriatrics & Gerontology26
Repeated Botulinum Toxin Type A Injections on... | 临床试验